Company news

Monte Rosa Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

May 20, 2024

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

May 15, 2024

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

May 1, 2024

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 13, 2024

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

March 10, 2024

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

January 7, 2024

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

November 6, 2023

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

October 25, 2023

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

October 16, 2023

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

October 16, 2023

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

July 25, 2023

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

May 22, 2023

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

March 22, 2023

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

January 8, 2023

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

November 9, 2022

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

October 31, 2022

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

October 30, 2022

Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

September 5, 2022

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

August 10, 2022

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

May 10, 2022

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

April 7, 2022

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

March 28, 2022

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

January 24, 2022

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

December 1, 2021

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

November 9, 2021

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer

October 6, 2021

Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference

September 29, 2021

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

September 9, 2021

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

August 11, 2021

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

June 22, 2021

← Newer news releases

Calls

Decks

The 5 newest of 23 decks. Every deck is listed under its year.